Aclarion Partners with New Jersey Surgeon to Enhance Personal Injury and Workers Compensation Market
TL;DR
Nociscan provides objective data for personal injury and workers compensation claims, giving an advantage in settlement negotiations.
Nociscan uses MRS data and proprietary algorithms to noninvasively distinguish between painful and nonpainful discs in the lumbar spine.
Nociscan aims to provide the right treatments and financial compensation to patients suffering from chronic low back pain, improving their quality of life.
Aclarion, Inc. is leveraging biomarkers and AI to help physicians identify chronic low back pain, revolutionizing the healthcare technology industry.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc. (Nasdaq: ACON, ACONW) has launched a new program aimed at enhancing the evaluation and treatment of chronic low back pain within the personal injury and workers compensation markets in New Jersey. The initiative will be led by Dr. Justin Kubeck, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ.
The program will focus on creating a statewide network of providers who will use Nociscan, a technology that leverages biomarkers and proprietary augmented intelligence algorithms to help physicians pinpoint the source of chronic low back pain. This could be particularly beneficial in legal settings, where objective and definitive diagnoses are crucial.
Dr. Kubeck emphasized the importance of Nociscan in providing objective measurements that can support appropriate treatment pathways. He plans to educate the network of judges and lawyers involved in adjudicating personal injury and workers compensation claims about the value of Nociscan in improving the evaluation process.
The financial implications of neck and back injuries in personal injury and workers compensation claims are significant. In New Jersey, the average settlement for personal injury claims involving the neck and back is $918,967, while the national average for work-related accidents resulting in such injuries is $148,750. Nociscan's ability to measure biomarkers in the lumbar disc correlated to pain and structural integrity can provide critical data for forming and defending treatment plans.
Ryan Bond, Chief Strategy Officer of Aclarion, stated that once the program is established in New Jersey, the company plans to expand to other markets across the United States. According to Bond, the use of advanced biomarker identification available through Nociscan is a perfect fit for the personal injury and workers compensation population.
This initiative represents a significant step forward in the use of advanced medical technologies to improve patient outcomes and streamline the legal processes associated with personal injury and workers compensation claims.
Curated from NewMediaWire
